Combined RAS-RAF-MAPK and Histone Deacetylase (HDAC) pathways (RAS-MAPK/HDAC)

The combined RAS-RAF-MAPK and Histone Deacetylase (HDAC) pathways represent a therapeutic strategy targeting two distinct regulatory mechanisms in cancer. The RAS-RAF-MAPK pathway is a critical signal transduction cascade that regulates cell growth, differentiation, and survival, often constitutively active in human cancers due to mutations in RAS or BRAF (Source: NIH/NCI). Histone Deacetylases (HDACs) are enzymes that modify chromatin structure and regulate gene expression, often overexpressed in tumors to silence pro-apoptotic and tumor-suppressor genes (Source: PubMed, PMID: 22429478). Combining inhibitors of these two pathways, such as MEK inhibitors and HDAC inhibitors, is designed to achieve synergistic anti-tumor effects and overcome acquired resistance to MAPK-targeted therapies (Source: Clinical Cancer Research, DOI: 10.1158/1078-0432.CCR-17-2433). This dual approach promotes cell cycle arrest and apoptosis by simultaneously blocking survival signaling and inducing epigenetic reprogramming. Clinical trials have explored this combination in various solid tumors and hematological malignancies to improve patient outcomes where single-pathway inhibition has proven insufficient (Source: ClinicalTrials.gov).

Other names

MAPK/HDAC axisRAS-RAF-MEK-ERK and HDAC signalingMEK/HDAC dual inhibitionRAS/HDAC pathway combination

Simultaneous inhibition of the MAPK kinase cascade and HDAC enzymes to disrupt cell survival signaling and induce epigenetic-mediated apoptosis (Source: PubMed, PMID: 30333116).